There are currently 462 clinical trials in Rochester, New York looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Rochester, University of Rochester Medical Center, James P. Wilmot Cancer Center at University of Rochester Medical Center and Rochester Clinical Research, Inc.. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Vitamin D Dynamics in Women
NCT02705287
Recruiting
The goal of this project is to utilize stable isotopically labeled vitamin D3 and state of the art mass spectrometric methodology to assess vitamin D dynamics during pregnancy in relation to relation to obesity and vitamin D binding protein genotype. At the conclusion of this study, the investigators will have obtained novel information on the absorption and utilization of vitamin D in women and the degree to which vitamin D utilization during pregnancy is impacted by genetic ancestry, vitamin D... Read More
Gender:
FEMALE
Ages:
Between 20 years and 39 years
Trial Updated:
02/25/2025
Locations: University of Rochester, 518 Hylan Building, Rochester, New York
Conditions: Pregnancy
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Strong Memorial Hospital, Rochester, New York
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT04886531
Recruiting
Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A breast biopsy will be performed prior to Day 1 of week 4 of treatment. Following surgery, patients will receive standard of care HER2-directed and endocrine therapy at the treating physician's discretion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
Register for Updates
Randomized Trial Comparing Immediate Vs. Deferred Surgery for Symptomatic ERM
NCT05145491
Recruiting
Vitrectomy to remove an epiretinal membrane (ERM) is one of the most common procedures performed by retinal surgeons. Patients who present with significant macular changes on optical coherence tomography (OCT) but relatively good vision are often advised to defer surgery until vision declines to 20/40 or worse. However, it is unknown if delaying surgery, which allows the foveal architecture to remain compromised and potentially to deteriorate, results in worse visual acuity outcomes than if surg... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/18/2025
Locations: Retina Associates of Western NY, P.C., Rochester, New York
Conditions: Epiretinal Membrane
Register for Updates
EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND)
NCT06808880
Recruiting
The purpose of this research is to develop and validate a single gene Non-Invasive Prenatal Test. The development of this investigational single-gene noninvasive prenatal testing (sgNIPT) for conditions such as cystic fibrosis (CF), spinal muscular atrophy (SMA), Sickle cell disease, alpha thalassemia (a-thalassemia) and beta thalassemia (b-thalassemia) could provide information about the possibility that a child will be born with a serious health condition, in some cases in the absence of repro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: University of Rochester, Rochester, New York
Conditions: Single Gene NIPT
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688
Recruiting
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: University of Rochester, Rochester, New York
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
REBYOTA™ Prospective Registry
NCT05835219
Recruiting
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (prim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Ferring Investigational Site, Rochester, New York
Conditions: Recurrence of Clostridium Difficile Infection
Register for Updates
Geriatric Evaluation and Management with Survivorship Health Education (GEMS) for Older Survivors of Cancer
NCT05006482
Recruiting
This phase III cluster randomized trial compares the effect of geriatric evaluation and management with survivorship health education (GEMS) to usual care on patient-reported physical function in older survivors of cancer. Survivorship care for older adults of cancer usually consists of getting advice from their doctor. This advice may include how to do their daily activities, so they are less tired or how to manage multiple diseases, or long-term side effects from treatment. GEMS may help impro... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/13/2025
Locations: University of Rochester NCORP Research Base, Rochester, New York
Conditions: Malignant Solid Neoplasm
Register for Updates
Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.
NCT05592002
Recruiting
The solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
02/12/2025
Locations: University of Rochester, Rochester, New York
Conditions: Sleep Apnea, Obstructive
Register for Updates
Follow-up Visit of High Risk Infants
NCT00009633
Recruiting
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may... Read More
Gender:
ALL
Ages:
Between 18 months and 26 months
Trial Updated:
02/11/2025
Locations: University of Rochester, Rochester, New York
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates
Generic Database of Very Low Birth Weight Infants
NCT00063063
Recruiting
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.
Gender:
ALL
Ages:
14 days and below
Trial Updated:
02/11/2025
Locations: University of Rochester, Rochester, New York
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients with CtDNA-positive, Resected Stage II (high Risk) and Stage III Colorectal Cancer
NCT04486378
Recruiting
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Mayo Clinic Rochester, Rochester, New York
Conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III
Register for Updates